Global Alliance Formed to Expand Access to Personalized Cancer Testing
Salt Lake City, Monday, 20 July 2026.
Burning Rock and Myriad Genetics have partnered to expand advanced genomic testing globally, introducing new tools to precisely evaluate prostate cancer and guide personalized treatment decisions.
A Strategic Leap in Precision Oncology
On July 17, 2026, with global announcements continuing through July 20, 2026, Burning Rock Biotech Limited (NASDAQ: BNR) and Myriad Genetics, Inc. (NASDAQ: MYGN) announced a new global technology licensing and strategic partnership [1][2][4]. This alliance is designed to advance next-generation sequencing (NGS)-based Homologous Recombination Deficiency (HRD) testing worldwide, representing a significant expansion of their existing collaboration [2][3][4]. By integrating Myriad’s proprietary companion diagnostic algorithms with Burning Rock’s extensive footprint in oncology testing, the deal aims to lower barriers to personalized cancer care on a global scale [1][2][3].
Expanding the Technological Frontier with prGIS
Under the newly expanded agreement, Burning Rock will integrate Myriad’s prostate Genomic Instability Score (prGIS) algorithm into the existing myChoice HRD Plus platform [1][2][4]. The prGIS algorithm evaluates critical genomic scars, specifically measuring Telomeric Allelic Imbalance (TAI), Large-scale State Transitions (LST), and Genome-Wide Imbalance (GWI) [1][2][4]. This integration will allow clinicians to precisely determine the HRD status of prostate cancer patients, providing vital data to guide individualized treatment decisions [4].
Global CDx Scale and Pharmaceutical Synergy
A primary objective of this expanded partnership is to provide global pharmaceutical companies with highly flexible and scalable companion diagnostic (CDx) solutions [1][2][4]. By utilizing the enhanced myChoice HRD Plus and the upcoming OncoScreen Plus-based kits, biopharma developers can streamline clinical trials, improve molecular profiling, and accelerate targeted drug development [1][3][4]. This initiative directly supports Burning Rock’s “One Assay for All” global strategy, which aims to deliver highly efficient molecular diagnostics to patients worldwide [1][4].
The Path Forward for Personalized Medicine
This strategic alliance represents a mutually beneficial expansion for both organizations [GPT]. For Myriad Genetics, a pioneer in molecular diagnostics, the agreement monetizes its sophisticated algorithms across high-growth international markets [4][GPT]. For Burning Rock, the partnership secures the advanced technology required to scale its oncology testing capabilities outside of China [4]. Although specific delivery dates or commercial timelines for the global rollout of the new OncoScreen Plus-based kits have not yet been disclosed [alert! ‘No specific delivery dates or timelines have been provided for the new HRD testing kit launch’], the deal represents a clear step forward in the global commercialization of personalized medicine [1][2][3].